Michael B Hoffman, a director at Annovis Bio, Inc., buys $5M of stock
The director paid an average of $1.00 a share, according to a Form 4 filed with the SEC on Nov 6. Information only, not investment advice.
Michael B Hoffman, a director of Annovis Bio, Inc. (ANVS), bought 5,000,000 shares on Nov 6 at an average price of $1.00, a total of $5 million, according to a Form 4 filed with the SEC on Nov 6.
It is an open-market purchase (transaction code P) of common stock, the kind of trade insiders make with their own money. After the trade, the filing lists 8,364,883 shares held.
The trade was reported within two business days, as Section 16 requires.
Details from the SEC filing:
| Company | Annovis Bio, Inc. (ANVS) |
|---|---|
| Insider | Michael B Hoffman |
| Role | Director |
| Transaction | Open-market purchase (code P) |
| Shares | 5,000,000 |
| Average price | $1.00 |
| Value | $5,000,000 |
| Trade date | Nov 6, 2026 |
| Filed with the SEC | Nov 6, 2026, 4:30 PM ET |
| Shares held after | 8,364,883 |
| Ownership | Direct |
| Rule 10b5-1 plan | Not marked in the filing |
Open the full breakdown of this ANVS trade
Read the daily insider trading roundup · Follow ANVS for the next insider trade
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
Related Articles
- Insider Trading News
Orbimed Advisors LLC, a director at Aspen Neuroscience, Inc., purchases $15M of stock
- Insider Trading News
RA Capital Management, L.P., a director at Bambusa Therapeutics, Inc., buys $46.6M of stock
- Insider Trading News
10% owner Bo Niclas Adler buys $108,000 of Visium Technologies, Inc. stock
- Insider Trading News
Three insiders buy Bambusa Therapeutics, Inc. shares, $58.6M in total
- Insider Trading News
Aspen Neuroscience, Inc. insider Peter A. Thompson purchases $15M in ASPE shares